In this article, we will look at the 10 High Growth Stocks Insiders Are Buying.
Insider buying tends to get attention because it signals that company executives are putting personal capital behind their own businesses. When insider purchases line up with strong earnings growth, improving revisions, or a better sector backdrop, the signal becomes harder to dismiss.
Tweedy, Browne describes the appeal as an “insider’s edge,” noting that insider buying may suggest executives “believe the stock price will increase,” while also warning it is “not a ‘sure thing’ in investing.” Insider buying is a clue, not proof. BlackRock adds that “Earnings strength is broadening” and points to a “new trend of upward revisions,” with “non-Mag 7 earnings power may be underappreciated.” In summary, growth opportunities may be spreading beyond the largest market leaders. Fidelity says “Tech is still king” and remains “ground zero for earnings growth,” adding that “technology remains difficult to replace” for investors looking for durable expansion.
Against this backdrop, high-growth stocks with insider buying offer an interesting mix of internal confidence and external earnings momentum. The key is finding cases where insiders are buying into improving fundamentals, not just trying to signal support after weakness. With that in mind, let’s take a look at the 10 High-Growth Stocks Insiders Are Buying.
Our Methodology
We used the Finviz screener to identify stocks with a significant increase in insider ownership over the last six months. We then filtered for stocks that have exhibited compounded annual earnings growth of at least 20% over the past three years and thereafter limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Sonida Senior Living, Inc. (NYSE:SNDA)
On June 29, 2026, RBC Capital analyst Ben Hendrix raised the firm’s price target on Sonida Senior Living, Inc. (NYSE:SNDA) to $48 from $45 and kept an Outperform rating on the shares. Hendrix said the updated price target better reflects the company’s momentum as it enters its compounding growth phase.
Earlier in June, Sonida Senior Living announced that Anton Nikodemus was appointed to the newly created role of Chief Operating Officer, effective June 15, 2026. Nikodemus brings 30 years of executive-level hospitality and operations leadership to Sonida and will oversee end-to-end operational performance across the portfolio.
Towards the end of May, Morgan Stanley raised the firm’s price target on Sonida Senior Living to $38 from $31 and kept an Equal Weight rating on the shares. Morgan Stanley updated its estimates as the CHP merger impact comes into focus, but took “a wait and see approach on execution.”
Sonida Senior Living, Inc. (NYSE:SNDA) owns and operates senior housing communities in the United States.
9. Zura Bio Limited (NASDAQ:ZURA)
On July 8, 2026, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive “differentiated efficacy” in two ongoing Phase 2 studies in hidradenitis suppurativa and systemic sclerosis.
On June 29, Zura Bio announced several tibulizumab program updates. The company completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS, exceeding the target enrollment with 247 participants enrolled. Zura also remained on track to complete enrollment of the Phase 2 TibuSURE trial of tibulizumab in adults with early diffuse cutaneous SSc in early July, with the trial already exceeding its target enrollment of 80 participants.
Topline data from TibuSHIELD are expected in the fourth quarter of 2026, while topline data from TibuSURE are expected in H1 2027. Zura also plans to initiate a Phase 2 study in a third immune-mediated indication by year-end 2026 and announce the new indication before study initiation. Also on June 29, Zura said it had cash and cash equivalents of $225.6M as of March 31, 2026, and continues to expect its existing cash to fund planned operations through at least the end of 2028.
Zura Bio Limited (NASDAQ:ZURA) develops medicines for autoimmune and inflammatory disorders in the United States.
